**Purpose:** Reduction mammoplasty occasionally reveals unsuspected proliferative lesions or carcinoma. Few studies examine incidence, risk factors, and outcomes in this population.

**Methods:** Retrospective review was performed between 2000 and 2012. Pathology was categorized as benign, proliferative, or cancer (DCIS or invasive).

**Results:** Five hundred seventy-three patients had 993 reduction mammaplasties (85% bilateral, 15% unilateral). Cancer was detected in 23 (2.3%) specimens and proliferative lesions in 148 (14.9%). Compared to patients with benign pathology, patients with proliferative lesions or cancer were older (p\<0.001), with larger BMI (p=0.001), increased unilateral procedures (p\<0.001) and more had a history of cancer (p\<0.001). On multivariate regression analysis, age and prior breast cancer were independent risk factors for proliferative lesions (OR 1.057, CI 1.039--1.075, p\<0.001 and OR 2.201, CI 1.291--3.752, p=0.004) and age significantly predicted cancer (OR 1.050, CI 1.009--1.093, p=0.015). There was no association with resection weight (p\>0.5). Fifty-four percent of patients with proliferative lesions and no history of cancer had a change in management with increased surveillance, hormones, radiation, chemotherapy, or surgery. If there was a history of cancer, 31% had a change in management. Of patients with DCIS or cancer, all required treatment.

**Conclusion:** Proliferative lesions of the breast may be more common that previously reported. Age and a history of breast cancer increase risk for proliferative lesions. All should be referred to oncology.
